🚀 VC round data is live in beta, check it out!
Citius Oncology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Citius Oncology and similar public comparables like Botanix Pharmaceuticals, Instil Bio, Pentixapharm Holding, Türk İlaç and more.
Citius Oncology Overview
About Citius Oncology
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
Founded
2021
HQ
Employees
0
Website
Sectors
Financials (LTM)
EV
$55M
Citius Oncology Financials
Citius Oncology reported last 12-month revenue of $20M.
In the same LTM period, Citius Oncology generated had net loss of ($21M).
Revenue (LTM)
Citius Oncology P&L
In the most recent fiscal year, Citius Oncology reported revenue of — and EBITDA of ($23M).
Citius Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $20M | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($23M) | XXX | XXX | XXX |
| EBIT Margin | (61%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($21M) | XXX | ($25M) | XXX | XXX | XXX |
| Net Margin | (103%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Citius Oncology Stock Performance
Citius Oncology has current market cap of $58M, and enterprise value of $55M.
Market Cap Evolution
Citius Oncology's stock price is $0.66.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $55M | $58M | 2.3% | XXX | XXX | XXX | $-0.28 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCitius Oncology Valuation Multiples
Citius Oncology trades at 2.7x EV/Revenue multiple, and (2.3x) EV/EBITDA.
EV / Revenue (LTM)
Citius Oncology Financial Valuation Multiples
As of April 11, 2026, Citius Oncology has market cap of $58M and EV of $55M.
Equity research analysts estimate Citius Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Citius Oncology has a P/E ratio of (2.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $58M | XXX | $58M | XXX | XXX | XXX |
| EV (current) | $55M | XXX | $55M | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.3x) | XXX | XXX | XXX |
| EV/EBIT | (4.4x) | XXX | (2.3x) | XXX | XXX | XXX |
| P/E | (2.8x) | XXX | (2.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Citius Oncology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Citius Oncology Margins & Growth Rates
Citius Oncology's revenue in the last 12 month grew by 296%.
Citius Oncology Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 296% | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 10% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 26% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Citius Oncology Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Botanix Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Instil Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Pentixapharm Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Türk İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| MiNK Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Citius Oncology M&A Activity
Citius Oncology acquired XXX companies to date.
Last acquisition by Citius Oncology was on XXXXXXXX, XXXXX. Citius Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Citius Oncology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCitius Oncology Investment Activity
Citius Oncology invested in XXX companies to date.
Citius Oncology made its latest investment on XXXXXXXX, XXXXX. Citius Oncology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Citius Oncology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Citius Oncology
| When was Citius Oncology founded? | Citius Oncology was founded in 2021. |
| Where is Citius Oncology headquartered? | Citius Oncology is headquartered in United States. |
| How many employees does Citius Oncology have? | As of today, Citius Oncology has over 0 employees. |
| Who is the CEO of Citius Oncology? | Citius Oncology's CEO is Leonard L. Mazur. |
| Is Citius Oncology publicly listed? | Yes, Citius Oncology is a public company listed on Nasdaq. |
| What is the stock symbol of Citius Oncology? | Citius Oncology trades under CTOR ticker. |
| When did Citius Oncology go public? | Citius Oncology went public in 2024. |
| Who are competitors of Citius Oncology? | Citius Oncology main competitors are Botanix Pharmaceuticals, Instil Bio, Pentixapharm Holding, Türk İlaç. |
| What is the current market cap of Citius Oncology? | Citius Oncology's current market cap is $58M. |
| What is the current revenue of Citius Oncology? | Citius Oncology's last 12 months revenue is $20M. |
| What is the current revenue growth of Citius Oncology? | Citius Oncology revenue growth (NTM/LTM) is 296%. |
| What is the current EV/Revenue multiple of Citius Oncology? | Current revenue multiple of Citius Oncology is 2.7x. |
| Is Citius Oncology profitable? | No, Citius Oncology is not profitable. |
| What is the current net income of Citius Oncology? | Citius Oncology's last 12 months net income is ($21M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.